Ⅰ. Reserach purpose
Development of control strategies for islet allograft rejection in sensitized recipients
Ⅱ. Research contents
1. Control of islet allograft rejection in cellular sensitized recipients
1) Establishment of cellular sensitized mod...
Ⅰ. Reserach purpose
Development of control strategies for islet allograft rejection in sensitized recipients
Ⅱ. Research contents
1. Control of islet allograft rejection in cellular sensitized recipients
1) Establishment of cellular sensitized models
BALB/C islet allograft survival rates were significantly lower in C57BL/6 mice
sensitized with BALB/c splenocytes than in naive B6 mice (P=0.0389)
2) Development of antirejection immune modulation protocols for cellular sensitized models
(1) in vitro immunosuppressive activity (MLR)
● Rapamycin had the strongest suppressive activity for memory response. Anti-OX-40L antibodies, and 5-azacytidine suppressed proliferation of memory T cells, while bortezomib (a proteozome inhibitor) decreased survival of memory T cells
(2) in vivo immunosuppressive activity in cellular sensitized recipients
● Combination therapy of anti-CD40L, rapamycin and anti-OX-40L antibodies prolonged islet allograft survival in sensitized recipients.
● When IL-2/anti-IL-2 complex, bortezomib or thalidomide was combined, islet allograft survival was significantly prolonged in naive recipients, whereas islet allograft survival in sensitized recipients was not significantly prolonged. 3) Immunomodulatory mechanisms for celluar memory response in islet allgraft rejection
(1) Comparison between no treatment and combination therapy of anti-CD40L/Rapamycin/anti-CD40L in cellular sensitized recipients with islet allograft
(2) Weaker intragraft infiltration of inflammatory cells in the combination therapy group 1 week after transplantation (immunohistochemistry) than in the control group
(3) No difference in expression of IFN-g, IL-4, IL-10, TGF-b, or Foxp3 in draining lymph node 1 week after transplantation (real time PCR)
...[중략] 원문참조